01801.HK
Innovent Biologics, Inc.
HKSE · Healthcare · Biotechnology · CN
HKD 102.40
−0.19%Margins
Gross margin
79.0%
EBITDA margin
12.2%
EBIT margin
9.6%
Net margin
8.7%
FCF margin
41.0%
11.3%
Return on equity
5.6%
Return on assets
11.3%
Return on invested capital
0.68x
Asset turnover
HKD 13.5B
Cash from operations
HKD 26
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026